Trial Profile
A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study of the Analgesic Efficacy And Study of Tanezumab in Patients With Osteoarthritis Of The Hip or Knee
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Naproxen
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Nov 2020 Results of a pooled analysis of data pooled from 6 trials assessing the relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis published in the International Journal of Clinical Pharmacology and Therapeutics
- 28 Jun 2010 Actual patient number (849) added as reported by ClinicalTrials.gov.
- 23 Jun 2010 Status changed from recruiting to suspended, as requested by the US FDA due to reports of worsening osteoarthritis, according to a Pfizer media release.